BioAmber Inc. announced today that the Company has entered into a mutual separation agreement with Mario Saucier, in connection with his departure from his role of Chief Financial Officer effective March 28, 2017.
BioAmber intends to initiate a search for a replacement CFO and until such time, Raymond J. Land, the current Chairman of the Board, has been appointed as the company’s interim Chief Financial Officer effective March 28, 2017.
Mr. Land has served on BioAmber’s Board since 2011. Prior to his retirement, Mr. Land served as Sr. VP and CFO of Clarient, Inc., a cancer diagnostics company, Sr. VP and CFO of Safeguard Scientifics, Inc., a venture capital firm, and Sr. VP and CFO for Genencor International Inc., from 1997 until its acquisition in 2005. Mr. Land has also held various positions at Campbell Soup Company Inc. and at Coopers & Lybrand, an accounting firm. – See more at: http://investor.bio-amber.com/#committees
Source: BioAmber
Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.
Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.
The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).
